Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMF3AN7)

Drug Name
Loratadine Drug Info
Synonyms
Aerotina; Alarin; Alavert; Alerpriv; Allertidin; Anhissen; Biloina; Bonalerg; Civeran; Claratyne; Clarinase; Claritin; Claritine; Clarityn; Clarityne; Clarium; Fristamin; Histaloran; Lergy; Lertamine; Lesidas; Lisino; Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadinum; Loratidine; Loratyne; Loraver; Lorfast; Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinomex; Roletra; Sanelor; Sensibit; Sohotin; Tadine; Velodan; Versal; Zeos; Bedix Loratadina; Claratyne Cold; Claratyne Decongestant; Clarinase Reperabs; Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Clarityne Dy Repetabs; Loratadina [Spanish]; Loratadine Redidose; Loratadine Wyeth Brand; Loratadinum [Latin]; Sinhistan Dy; Talorat Dy; Wyeth Brand of Loratadine; L 9664; Sch 29851; Sch29851; Alavert (TN); AllergyX (TN); Children's Claritin; Claritin (TN); Claritine (TN); Clarityn (TN); Clarityne (TN); Clarityne-D; Flonidan (TN); Fristamin (TN); Lomilan (TN); Lorfast (TN); Rinolan (TN); Roletra (TN); Sch-29851; Symphoral (TN); Tidilor (TN); Alavert, Claritin, Loratadine; Loratadine [USAN:BAN:INN]; Loratadine (JAN/USAN/INN); Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; 1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester
Therapeutic ClassAntihistamines
Cross-matching ID
PubChem CID
3957
ChEBI ID
CHEMBL998
CAS Number
CAS 79794-75-5
TTD Drug ID
D06ABF
VARIDT Drug ID
DR00541
INTEDE Drug ID
DR0977
ACDINA Drug ID
D00374

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Gap junction 1.81 1.14e-1 72/88 (81.82%) GNAI1;TUBB2A;GUCY1A1;...
Cocaine addiction 1.70 2.53e-1 42/49 (85.71%) GNAI1;GNAS;CREB1;...
Renin secretion 1.69 1.89e-1 61/69 (88.41%) GNAI1;GUCY1A1;GNAS;...
Primary bile acid biosynthesis 1.69 1.50e-1 15/17 (88.24%) SCP2;SLC27A5;AKR1D1;...
Amphetamine addiction 1.68 1.43e-1 57/69 (82.61%) GNAS;CREB1;GRIA2;...
Purine metabolism 1.66 1.62e-1 102/129 (79.07%) GUCY1A1;ADK;PDE1A;...
Alcoholism 1.62 1.95e-1 86/186 (46.24%) GNAI1;HAT1;GNAS;...
Oxytocin signaling pathway 1.59 2.39e-1 128/154 (83.12%) GNAI1;GUCY1A1;GNAS;...
Dopaminergic synapse 1.58 2.22e-1 115/132 (87.12%) GNAI1;GNAS;PPP2R3C;...
B cell receptor signaling pathway 1.57 2.10e-1 71/81 (87.65%) KRAS;BLNK;IFITM1;...
Apelin signaling pathway 1.57 2.00e-1 117/137 (85.4%) GNAI1;SPP1;CDH1;...
Type I diabetes mellitus 1.56 1.95e-1 38/43 (88.37%) CPE;PTPRN2;FAS;...
Biosynthesis of unsaturated fatty acids 1.51 2.68e-1 21/27 (77.78%) SCD;SCP2;HACD3;...
Vibrio cholerae infection 1.50 2.69e-1 44/50 (88%) GNAS;ADCY3;PRKACB;...
Vasopressin-regulated water reabsorption 1.50 2.53e-1 40/44 (90.91%) GNAS;AQP4;CREB1;...
Phagosome 1.43 4.32e-1 118/152 (77.63%) TUBB2A;DYNC1I1;ITGAV;...
Prion disease 1.42 4.08e-1 209/273 (76.56%) HSPA8;TUBB2A;EGR1;...
Parkinson disease 1.42 4.17e-1 176/249 (70.68%) GNAI1;TUBB2A;GNAS;...
Proteasome 1.41 4.08e-1 44/46 (95.65%) PSMA7;PSMD8;PSMD14;...
Amino sugar and nucleotide sugar metabolism 1.39 4.50e-1 38/48 (79.17%) GMDS;UGP2;HEXB;...
Cellular senescence 1.39 4.35e-1 139/156 (89.1%) E2F2;CCNB2;KRAS;...
Fatty acid elongation 1.38 4.20e-1 19/27 (70.37%) HACD3;ELOVL5;ELOVL6;...
Protein processing in endoplasmic reticulum 1.38 4.20e-1 127/171 (74.27%) HSPA8;HERPUD1;PDIA3;...
Long-term depression 1.38 4.03e-1 55/60 (91.67%) GNAI1;GUCY1A1;GNAS;...
Oxidative phosphorylation 1.38 3.91e-1 93/133 (69.92%) PPA1;COX15;ATP5MC2;...
Leukocyte transendothelial migration 1.36 4.10e-1 90/114 (78.95%) GNAI1;VCAM1;CLDN8;...
D-Glutamine and D-glutamate metabolism 1.34 4.55e-1 5/5 (100%) GLUD1;GLUD2
NF-kappa B signaling pathway 1.29 4.47e-1 90/104 (86.54%) CXCL2;RELB;CXCL3;...
MAPK signaling pathway 1.29 4.45e-1 272/294 (92.52%) HSPA8;AREG;RELB;...
Circadian entrainment 1.28 4.48e-1 85/97 (87.63%) GNAI1;GUCY1A1;GNAS;...
Mannose type O-glycan biosynthesis -1.24 4.87e-1 14/23 (60.87%) B4GALT2;POMT2;CHST10;...
Ubiquitin mediated proteolysis -1.25 4.91e-1 87/140 (62.14%) CBLC;CDC16;RNF7;...
African trypanosomiasis -1.27 4.47e-1 32/37 (86.49%) PLCB3;PLCB4;LAMA4;...
Regulation of lipolysis in adipocytes -1.28 4.37e-1 52/55 (94.55%) PIK3CD;IRS2;PIK3CB;...
Steroid hormone biosynthesis -1.29 4.11e-1 43/61 (70.49%) UGT2B28;UGT2B17;CYP3A7;...
beta-Alanine metabolism -1.29 4.20e-1 25/30 (83.33%) ECHS1;ALDH6A1;SMOX;...
Inositol phosphate metabolism -1.29 4.31e-1 66/73 (90.41%) PIK3CD;SACM1L;PIK3CB;...
ECM-receptor interaction -1.30 4.31e-1 80/88 (90.91%) COL4A2;HMMR;THBS1;...
SNARE interactions in vesicular transport -1.30 4.39e-1 19/33 (57.58%) STX4;GOSR1;STX3;...
Cholesterol metabolism -1.33 3.83e-1 44/50 (88%) SCARB1;APOE;APOA4;...
Systemic lupus erythematosus -1.33 3.99e-1 45/135 (33.33%) FCGR2A;SNRPB;CD40;...
One carbon pool by folate -1.33 4.13e-1 15/20 (75%) TYMS;MTHFD1;ALDH1L1;...
Amoebiasis -1.34 4.07e-1 99/102 (97.06%) C9;TGFB1;PIK3CD;...
Ascorbate and aldarate metabolism -1.35 4.02e-1 15/30 (50%) UGT2B28;UGT2B17;UGT2B15;...
Ovarian steroidogenesis -1.35 4.15e-1 41/51 (80.39%) IGF1R;SCARB1;PTGS2;...
Folate biosynthesis -1.36 4.12e-1 23/26 (88.46%) PTS;AKR1B1;ALPL;...
Thyroid hormone synthesis -1.37 4.07e-1 66/75 (88%) ATP1B3;PAX8;ADCY7;...
Aldosterone-regulated sodium reabsorption -1.37 4.24e-1 34/37 (91.89%) ATP1B1;PIK3CD;PIK3CB;...
Glycerophospholipid metabolism -1.37 4.51e-1 71/98 (72.45%) PCYT1A;GNPAT;DGKG;...
Retinol metabolism -1.38 4.51e-1 41/68 (60.29%) UGT2B28;RETSAT;UGT2B17;...
Neomycin, kanamycin and gentamicin biosynthesis -1.40 4.12e-1 5/5 (100%) HK2
Aldosterone synthesis and secretion -1.41 4.28e-1 85/98 (86.73%) CYP11B2;CACNA1F;KCNJ5;...
Renin-angiotensin system -1.42 4.34e-1 20/23 (86.96%) KLK2;PRCP;MME;...
Carbohydrate digestion and absorption -1.43 4.60e-1 37/47 (78.72%) SI;GNAT3;ATP1B1;...
Citrate cycle (TCA cycle) -1.44 4.71e-1 30/30 (100%) SUCLA2;ACO1;PC;...
PPAR signaling pathway -1.58 2.62e-1 66/74 (89.19%) FABP6;SLC27A2;CPT2;...
Fatty acid degradation -1.58 3.28e-1 40/43 (93.02%) ALDH1B1;ALDH7A1;CPT2;...
Fat digestion and absorption -1.69 1.31e-1 35/43 (81.4%) PNLIPRP2;SCARB1;APOA4;...
Type II diabetes mellitus -1.76 1.24e-1 42/46 (91.3%) MTOR;CACNA1C;PIK3CD;...
Glycerolipid metabolism -1.79 1.72e-1 44/61 (72.13%) TKFC;LIPG;DGKG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H